Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT94MI001099Aexternal-prioritypatent/ITMI941099A1/en
Priority claimed from ITMI950494external-prioritypatent/IT1293558B1/en
Application filed by Smithkline Beecham SfiledCriticalSmithkline Beecham S
Priority claimed from NZ287442Aexternal-prioritypatent/NZ287442A/en
Publication of NZ329979ApublicationCriticalpatent/NZ329979A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
Use of an NK3 receptor antagonist in the manufacture of a medicament for treating convulsive disorders, epilepsy, renal disorders, urinary incontinence, ocular inflammation, inflammatory pain, eating disorders, allergic rhinitis, neurodegenerative disorders, psoriasis, Huntingtons disease and depression.
NZ329979A1994-05-271995-05-23Use of NK3 receptor antagonists
NZ329979A
(en)
Use of 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz [B,E] oxepin-2-acetic acid for the manufacture of a medicament for treating non-allergic ophthalmic inflammatory disorders and for the prevention of ocular neovascularization.
Endothelin antagonists and endothelin synthase inhibitors for the prevention and treatment of uterine contraction disorders, preeclampsia, atherosclerotic vascular disease, hypertension and for hormone replacement therapy